Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019

Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019



According to the recently published report Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019; Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) pipeline Target constitutes close to 11 molecules.

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Tryptophan 2, 3-dioxygenase is an enzyme that plays a critical role in tryptophan metabolism by catalyzing the first and rate-limiting step of the kynurenine pathway. It has specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin.

The report Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019 outlays comprehensive information on the Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 7 and 1 respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Melanoma, Solid Tumor, Bladder Cancer, Colon Carcinoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer and Parkinsons Disease.

Scope
- The report provides a snapshot of the global therapeutic landscape for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
- The report reviews Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Overview
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Companies Involved in Therapeutics Development
CanBas Co Ltd
Emcure Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Jiangsu Hengrui Medicine Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Netherlands Translational Research Center BV
NewLink Genetics Corp
Shanghai De Novo Pharmatech Co Ltd
Syntekabio Inc
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Drug Profiles
DN-1406131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPL-1410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTI-1090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-01013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70099 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TDO for Parkinsons Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Dormant Products
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Product Development Milestones
Featured News & Press Releases
Jul 31, 2018: Approval for clinical trial for class I new chemical drugAnti-Tumor innovative drug (LY01013) in China
Jun 06, 2018: De Novo Pharmatech receives approval to initiate clinical trials in China with IDO1/TDO2 inhibitor DN1406131
Jan 05, 2018: De Novo Pharmatech submitted the IND application of DN1406131 to FDA
Dec 04, 2017: De Novo Pharmatech submitted the IND application of DN1406131 to CFDA
Feb 10, 2015: IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs
Feb 06, 2015: IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at Keystone Tumor Immunology Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by CanBas Co Ltd, H2 2019
Pipeline by Emcure Pharmaceuticals Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by Luye Pharma Group Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Netherlands Translational Research Center BV, H2 2019
Pipeline by NewLink Genetics Corp, H2 2019
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H2 2019
Pipeline by Syntekabio Inc, H2 2019
Dormant Projects, H2 2019

List Of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019

Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019According to the recently published report Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2019; Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase

USD 3500 View Report

Europe INN Tryptophan Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe INN Tryptophan market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by the

USD 3000 View Report

Global Indoleamine 2,3 Dioxygenase 1 Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Indoleamine 2,3 Dioxygenase 1 is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by

USD 4000 View Report

North America Indoleamine 2,3 Dioxygenase 1 Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The North America Indoleamine 2,3 Dioxygenase 1 market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available